814 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019 http://www.zacks.com/stock/news/525940/alexion-alxn-down-on-news-of-cfo-clancys-departure-in-2019?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-525940 Sep 19, 2019 - Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma http://www.zacks.com/stock/news/524596/mercks-keytruda-combo-gets-fda-nod-for-endometrial-carcinoma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-524596 Sep 18, 2019 - Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More http://www.zacks.com/stock/news/524561/biotech-stock-roundup-biib-halts-ad-study-amgn-posts-positive-mm-drug-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-524561 Sep 18, 2019 - Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold http://www.zacks.com/stock/news/522713/the-zacks-analyst-blog-highlights-amgen-tokyo-electron-and-kinross-gold?cid=CS-ZC-FT-press_releases-522713 Sep 17, 2019 - The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold
Top Stock Picks for Week of September 16, 2019 http://www.zacks.com/stock/news/521513/top-stock-picks-for-week-of-september-16-2019?cid=CS-ZC-FT-video_blog-521513 Sep 16, 2019 - A Biotech Pioneer and an E-Commerce Giant.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study http://www.zacks.com/stock/news/520871/amgens-kyprolis-combo-improves-pfs-in-multiple-myeloma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-520871 Sep 16, 2019 - Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland http://www.zacks.com/stock/news/516985/vertex-gains-reimbursement-for-orkambi-symkevi-in-scotland?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516985 Sep 13, 2019 - Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
Top Research Reports for Amgen, Cisco & Berkshire Hathaway http://www.zacks.com/research-daily/515077/top-research-reports-for-amgen-cisco-berkshire-hathaway?cid=CS-ZC-FT-research_daily-515077 Sep 12, 2019 - Top Research Reports for Amgen, Cisco & Berkshire Hathaway
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance http://www.zacks.com/stock/news/515058/puma-biotechs-snda-for-nerlynx-combo-gets-fda-acceptance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-515058 Sep 12, 2019 - The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Ultragenyx to Submit sBLA for Label Expansion of Crysvita http://www.zacks.com/stock/news/513339/ultragenyx-to-submit-sbla-for-label-expansion-of-crysvita?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-513339 Sep 11, 2019 - Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.

Pages: 1...678910111213141516...82

<<<Page 11>